Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Michael Acceptors as Cysteine Protease Inhibitors

Author(s): Maria M.M. Santos and Rui Moreira

Volume 7, Issue 10, 2007

Page: [1040 - 1050] Pages: 11

DOI: 10.2174/138955707782110105

Price: $65

conference banner
Abstract

Cysteine proteases selectively catalyze the hydrolysis of peptide bonds. Uncontrolled, unregulated, or undesired proteolysis can lead to many disease states including emphysema, stroke, viral infections, cancer, Alzheimers disease, inflammation, and arthritis. Cysteine proteases inhibitors thus have considerable potential utility for therapeutic intervention in a variety of disease states. This review emphasizes on the new developments from literature reports on Michael acceptors as potential cysteine protease inhibitors, namely vinyl sulfones, α,β-unsaturated carbonyl derivatives and aza-peptides. These compounds irreversibly alkylate the active site cysteine residue via conjugate addition. Examples of Michael acceptors inhibitors that have already progressed to clinical testing are also presented.

Keywords: Cysteine protease inhibitors, vinyl sulfone, α,β-unsaturated carbonyl derivative, aza-peptide Michael acceptor, K-777, Ruprintivir


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy